Live Breaking News & Updates on Agios Pharmaceuticals Trading Down

Stay updated with breaking news from Agios pharmaceuticals trading down. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Agios Pharmaceuticals, Inc. to Post Q2 2025 Earnings of ($1.62) Per Share, Zacks Research Forecasts (NASDAQ:AGIO)

Agios Pharmaceuticals, Inc. to Post Q2 2025 Earnings of ($1.62) Per Share, Zacks Research Forecasts (NASDAQ:AGIO)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United States , James William Burns , Jacqualyna Fouse , Goldman Sachs Group , Securities Exchange Commission , Cantor Fitzgerald , Royal Bank , Norges Bank , Dimensional Fund Advisors , Agios Pharmaceuticals , Jpmorgan Chase Co , News Ratings For Agios Pharmaceuticals Daily , Agios Pharmaceuticals Inc , Zacks Research , Frazier Life Sciences Management , Agios Pharmaceuticals Trading Down , Armistice Capital , Free Report , Agios Pharmaceutical , Get Free Report , Pharmaceuticals Trading Down , Fund Advisors , Director Jacqualyn , Exchange Commission , Agios Pharmaceuticals Daily ,

Agios Pharmaceuticals (NASDAQ:AGIO) Announces Quarterly Earnings Results

Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.64) by $0.19, Briefing.com reports. Agios Pharmaceuticals had a negative return on equity of 39.74% and a negative net margin of 1,199.26%. The company […] ....

United States , James William Burns , Brian Goff , News Ratings For Agios Pharmaceuticals Daily , Securities Exchange Commission , Royal Bank , Agios Pharmaceuticals Trading Down , Agios Pharmaceuticals Inc , Cantor Fitzgerald , Agios Pharmaceuticals , Jpmorgan Chase Co , Earnings History For Agios Pharmaceuticals , Agios Pharmaceuticals Company Profile , Goldman Sachs Group , Get Free Report , Pharmaceuticals Trading Down , Exchange Commission , Agios Pharmaceuticals Daily , Nasdaq Agio ,

Agios Pharmaceuticals (NASDAQ:AGIO) Issues Earnings Results, Beats Estimates By $0.19 EPS

Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.64) by $0.19, Briefing.com reports. Agios Pharmaceuticals had a negative return on equity of 38.08% and a negative net margin of 1,312.64%. The company had […] ....

United States , Brian Goff , James William Burns , Insider Activity At Agios Pharmaceuticals , Goldman Sachs Group , Cantor Fitzgerald , Agios Pharmaceuticals Trading Down , Jpmorgan Chase Co , Royal Bank , Securities Exchange Commission , Agios Pharmaceuticals Inc , Agios Pharmaceuticals , News Ratings For Agios Pharmaceuticals Daily , Earnings History For Agios Pharmaceuticals , Get Free Report , Pharmaceuticals Trading Down , Exchange Commission , Agios Pharmaceuticals Daily , Nasdaq Agio ,

Agios Pharmaceuticals (NASDAQ:AGIO) Announces Quarterly Earnings Results

Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.64) by $0.19, Briefing.com reports. The firm had revenue of $8.19 million for the quarter, compared to analyst estimates of $8.37 million. Agios Pharmaceuticals […] ....

United States , James William Burns , Brian Goff , Agios Pharmaceuticals Inc , Royal Bank , Goldman Sachs Group , News Ratings For Agios Pharmaceuticals Daily , Agios Pharmaceuticals , Cantor Fitzgerald , Agios Pharmaceuticals Trading Down , Agios Pharmaceuticals Company Profile , Earnings History For Agios Pharmaceuticals , Jpmorgan Chase Co , Get Free Report , Pharmaceuticals Trading Down , Agios Pharmaceuticals Daily , Nasdaq Agio ,

Agios Pharmaceuticals (NASDAQ:AGIO) Price Target Lowered to $42.00 at Royal Bank of Canada

Agios Pharmaceuticals (NASDAQ:AGIO – Free Report) had its price objective lowered by Royal Bank of Canada from $43.00 to $42.00 in a research note released on Friday morning, Benzinga reports. The brokerage currently has an outperform rating on the biopharmaceutical company’s stock. AGIO has been the subject of a number of other reports. The Goldman […] ....

Tsveta Milanova , Jacqualyna Fouse , Securities Exchange Commission , Vanguard Group Inc , Goldman Sachs Group , Metlife Investment Management , Agios Pharmaceuticals Trading Down , Envestnet Asset Management Inc , Dimensional Fund Advisors , Cantor Fitzgerald , News Ratings For Agios Pharmaceuticals Daily , Agios Pharmaceuticals Inc , Royal Bank , Agios Pharmaceuticals , Free Report , Pharmaceuticals Trading Down , Get Free Report , Director Jacqualyn , Exchange Commission , Asset Management , Life Investment Management , Fund Advisors , Asset Management Gmbh , Vanguard Group , Agios Pharmaceuticals Daily , Nasdaq Agio ,